Get the Stockscreener App
41.50
2.21%
-0.94
Tarsus Pharmaceuticals Inc stock is traded at $41.50, with a volume of 442.11K.
It is down -2.21% in the last 24 hours and up +3.23% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$42.44
Open:
$42.54
24h Volume:
442.11K
Relative Volume:
0.70
Market Cap:
$1.74B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-8.944
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
-4.05%
1M Performance:
+3.23%
6M Performance:
-14.92%
1Y Performance:
+46.95%
1-Day Range:
$40.75
$42.54
1-Week Range:
$40.75
$43.55
52-Week Range:
$20.08
$57.28
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
41.50 | 1.78B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Bank of New York Mellon Corp Sells 915 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Should I buy Tarsus Pharmaceuticals Inc. stock before earningsHigh-yield investments - jammulinksnews.com
Is Tarsus Pharmaceuticals Inc. a good long term investmentOutstanding growth strategies - Autocar Professional
Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Path To Profitability - Yahoo Finance
Tarsus Pharmaceuticals Inc. Stock Analysis and ForecastHigh-return market picks - Autocar Professional
What analysts say about Tarsus Pharmaceuticals Inc. stockHigh-yield portfolio picks - jammulinksnews.com
Arizona State Retirement System Purchases 470 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
What drives Tarsus Pharmaceuticals Inc. stock priceBreakthrough wealth creation - Autocar Professional
What makes Tarsus Pharmaceuticals Inc. stock price move sharplyFree Stock Movement Tracking - Newser
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Tarsus Pharmaceuticals (TARS) and Abbott Laboratories (ABT) - The Globe and Mail
Tarsus Pharmaceuticals Shares Soar 4.47% on Strong Sales, Earnings - AInvest
Tarsus Pharmaceuticals: A Compelling Case for Investment in the Era of Anterior Segment Innovation - AInvest
Tarsus Pharmaceuticals: Making Big Strides (NASDAQ:TARS) - Seeking Alpha
William Blair Has Bearish Estimate for TARS Q2 Earnings - Defense World
What is William Blair’s Forecast for TARS FY2026 Earnings? - Defense World
How Tarsus Pharmaceuticals Inc. stock performs during market volatilityFree Investment Risk Control - Newser
Why Tarsus Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Return Potential - Newser
Bank of America Securities Reaffirms Buy Rating for Tarsus Pharmaceuticals at $68.00 - AInvest
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Amalgamated Bank - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Analysts - Defense World
(TARS) Investment Analysis - news.stocktradersdaily.com
Market Sentiment Around Loss-Making Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - simplywall.st
Janney Montgomery Scott LLC Sells 2,795 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals, Inc.(NasdaqGS:TARS) dropped from Russell Microcap Growth Index - MarketScreener
Tarsus Pharmaceuticals (NASDAQ:TARS) versus Protalix BioTherapeutics (NYSE:PLX) Financial Comparison - Defense World
Tarsus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Tarsus Pharmaceuticals Becomes Oversold (TARS) - Nasdaq
When (TARS) Moves Investors should Listen - news.stocktradersdaily.com
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Rhumbline Advisers Increases Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals’ SWOT analysis: XDEMVY’s success propels stock growth - Investing.com Australia
Tarsus Pharmaceuticals’ SWOT analysis: XDEMVY’s success propels stock growth By Investing.com - Investing.com India
Insider Sell: Aziz Mottiwala Sells 17,500 Shares of Tarsus Pharm - GuruFocus
Tarsus Pharmaceuticals CCO sells $765,800 in stock - Investing.com Australia
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):